Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corp ADR (NQ: LEGN )

45.02 +0.75 (+1.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corp ADR

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Will This 2020 Biotech IPO Crush the Market This Year?
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Product Safety Securities Market
Legend Biotech Announces Advancement of Global Manufacturing Infrastructure
From Legend Biotech
Via Business Wire
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings
From Legend Biotech
Via Business Wire
Legend Biotech-Janssen's Multiple Myeloma Cell Therapy Under Review In US
Legend Biotech Corporation (NASDAQ: LEGN) has announced that the FDA accepted for priority review the marketing application submitted by Janssen Biotech Inc... 
Via Benzinga
Exposures Product Safety
U.S. Food and Drug Administration Grants BCMA CAR-T Cilta-cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma
From Legend Biotech
Via Business Wire
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
Legend Biotech to Present at the Jefferies Virtual Healthcare Conference
From Legend Biotech Corporation
Via Business Wire
58 Biggest Movers From Yesterday
Gainers BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results. Ultralife Corporation (NASDAQ: ULBI)... 
Via Benzinga
42 Stocks Moving In Tuesday's Mid-Day Session
Gainers Agenus Inc. (NASDAQ: AGEN) shares surged 33.4% to $4.35. Bristol-Myers Squibb Co and Agenus entered into a global exclusive license agreement, under which Bristol Myers... 
Via Benzinga
Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights
From Legend Biotech Corporation
Via Business Wire
Week In Review: GenScript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
GenScript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to GenScript's Legend Biotech CAR-T subsidiary. Before the... 
Via Talk Markets
28 Stocks Moving in Friday's Pre-Market Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares rose 28.5% to $0.7451 in pre-market trading after the company reported better-than-expected Q1 sales. Bionano Genomics, Inc. (NASDAQ:... 
Via Benzinga
Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings
From Legend Biotech
Via Business Wire
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million... 
Via Talk Markets
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
From Legend Biotech Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.